Generic medicine makers prepare to launch affordable options after Novo's patent for Ozempic, Wegovy expires

Patent expirations for blockbuster drugs often lead to a surge in generic competition, making treatments more accessible and expanding market size, especially in price-sensitive markets like India.

• •India's obesity treatment market is set to expand rapidly.
• •Local drugmakers are preparing to release affordable versions of Novo Nordisk’s Ozempic and Wegovy.
• •Launches will occur following patent expiration.
• •Anticipated price drop could drive demand.
• •Clinics and hospitals may enhance obesity services to meet rising need.